1 |
Li S, Yu KD, Fan L, et al. Predicting breast cancer recurrence following breast- conserving therapy: a single-institution analysis consisting of 764 Chinese breast cancer cases. Ann Surg Oncol, 2011, 18(9): 2492-2499.
|
2 |
Kenneth WH, William FA, Susan SD, et al. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the national cancer institute. J Natl Cancer Inst, 2005, 97(13): 966-975.
|
3 |
Edges SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010, 17(6): 1471-1474.
|
4 |
Vermeulen PB, van Golen KL, Dirix LY. Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer: a review of the current knowledge. Cancer, 2010, 116(11 Suppl): 2748-2754.
|
5 |
Bertucci F, Finetti P, Rougemont J, et al. Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Cancer Res, 2005, 65(6): 2170-2178.
|
6 |
Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol, 2011, 22(3): 515-523.
|
7 |
Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, et al. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M.D. Anderson Cancer Center experience. Clin Breast Cancer, 2004, 4(6): 415-419.
|
8 |
Yamauchi H, Ueno NT. Targeted therapy in inflammatory breast cancer. Cancer, 2010, 116(11 Suppl): 2758-2759.
|
9 |
Viens P, Palangie T, Janvier M, et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer, 1999, 81(3): 449-456.
|
10 |
Somlo G, Frankel P, Chow W, et al. Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol, 2004, 22(10): 1839-1848.
|
11 |
Panades M, Olivotto IA, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol, 2005, 23(9): 1941-1950.
|
12 |
Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol, 2007, 18(12): 1927-1934.
|
13 |
Bristol IJ, Woodward WA, Strom EA, et al. Local-regional control of recurrent breast carcinoma after mastectomy: does hyperfractionated accelerated radiotherapy improve local control. Int J Radiat Oncol Biol Phys, 2008, 72(2): 474-484.
|
14 |
Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010, 375(9712): 377-384.
|
15 |
Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol, 2006, 24(5): 769-777.
|
16 |
Jhaveri KL, Teplinsky E, Arju R, et al. Hyperactivated mTOR and JAK2/STAT3 pathways: Crucial molecular drivers and potential therapeutic targets of inflammatory breast cancer (IBC). J Clin Oncol 31, 2013 (suppl; abstr 11106).
|
17 |
Specht JM, Kurland BF, Linden HM, et al. A phase II study evaluating the safety and efficacy of sunitinib with weekly paclitaxel followed by doxorubicin and daily oral cyclophosphamide plus G-CSF as neoadjuvant chemotherapy (NC) for locally advanced (LABC) or inflammatory breast cancer (IBC). J Clin Oncol 31, 2013 (suppl; abstr 1090).
|
18 |
Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 5).
|
19 |
Schlichting JA, Soliman AS, Schairer C, et al. Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990–2008. Breast Cancer Res Treat, 2012, 134(3): 1257-1268.
|
20 |
Harris EE, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J Radiat Oncol Biol Phys, 2003, 55(5): 1200-1208.
|
21 |
Li J, Gonzalez-Angulo AM, Allen PK, et al. Triple-negative subtype predicts poor overall survival and high loco-regional relapse in inflammatory breast cancer. Oncologist, 2011, 16(12): 1675-1683.
|